Brian M. Stuglik

Brian M. Stuglik (chief executive) discloses dealings in 2 companies, chiefly Verastem, Inc. and Puma Biotechnology, Inc. The record holds 48 filings, for trades running from 28 September 2018 to 16 December 2025.

Market trades split into 3 purchases (€6,275) and 31 sales (€301k). On balance, insiders were net sellers of €295k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 14 share grants. Since January 2025: no purchases and 5 sales on the market.

Half of the purchases are above €1,884 and half below. Clusters matter here: 3 out of 3 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. After 3 purchases with a full 90-day history, the hit rate stands at 0% and the median 90-day move at -48.5%. Past outcomes like these are no guarantee of what comes next.

On 18 December 2025 came the latest disclosure, an open-market sale for €4,603 in Verastem, Inc. The most recent open-market purchase was published on 2 October 2018, 2,943 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.